Skip to Content

New Drug Approvals Archive - November 2007

Get news by email or subscribe to our news feeds.

November 2007

November 6

Abilify (aripiprazole)

Patient Population Altered: October 29, 2007

November 9

Crestor (rosuvastatin calcium)

New Indication Approved: November 8, 2007

November 14

Mircera (epoetin beta-methoxy polyethylene glycol) Injection

Date of Approval: November 14, 2007
Company: Roche
Treatment for: Anemia Associated with Chronic Renal Failure

Mircera (epoetin beta-methoxy polyethylene glycol) is an erythropoiesis-stimulating agent indicated for the treatment of anemia associated with chronic renal failure.

Mircera (epoetin beta-methoxy polyethylene glycol) FDA Approval History

November 16

Seroquel XR (quetiapine)

New Indication Approved: November 15, 2007

Seroquel XR (quetiapine) FDA Approval History

November 20

Abilify (aripiprazole)

New Indication Approved: November 16, 2007

November 30

Cymbalta (duloxetine)

New Indication Approved: November 28, 2007

Cymbalta (duloxetine) FDA Approval History

November 29

Triesence (triamcinolone acetonide) Injectable Suspension

Date of Approval: November 29, 2007
Company: Alcon, Inc.
Treatment for: Temporal Arteritis, Uveitis

Triesence (triamcinolone acetonide) is a synthetic corticosteroid indicated for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Triesence (triamcinolone acetonide) FDA Approval History